Navigation Links
Indevus Announces Submission of New Drug Application
Date:8/28/2007

y the analysis of the safety measurements collected and the persistence with study treatment. Further, the spectrum of adverse events reported were comparable to other injectable hypogonadism treatments reported in the literature. There were no significant adverse changes in laboratory parameters with NEBIDO treatment.

About NEBIDO

NEBIDO(R) is a long-acting depot preparation of testosterone undecanoate, developed for the treatment of male hypogonadism. NEBIDO is expected to be the first three-month testosterone preparation available in the U.S. in the growing market for testosterone therapies. Indevus acquired U.S. rights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005.

About Hypogonadism

Male hypogonadism is an increasingly recognized medical condition characterized by a reduced or absent secretion of testosterone from the testes. Reduced testosterone levels can lead to health problems and significantly impair quality of life. Common effects of hypogonadism include decreased sexual desire, muscle loss and weakness, as well as an increased risk of osteoporosis. Today, there are an estimated four to five million men in the U.S. who suffer from hypogonadism. Of this group, less than ten percent are currently receiving treatment with testosterone therapy.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) XR and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA, for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(R) for bladder c
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting
2. Indevus Reports Positive Data From Phase III NEBIDO Trial
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)...  EndoChoice Holdings, Inc. (NYSE:  GI) announced today that ... on Thursday, August 6, 2015 before the market open. ... on Thursday, August 6, 2015 at 9:00 a.m. ET ... 807-9684 for domestic callers and (412) 317-5415 for international ... be available on the investor relations section of the ...
(Date:7/6/2015)... 2015  OrthoSpace Ltd. ("OrthoSpace" or "Company") announced ... in its US Investigational Device Exemption (IDE) pivotal ... single blinded control study that compares the Company,s ... partial repair for the treatment of full thickness ... commercially available outside of the United ...
(Date:7/6/2015)... - The Canadian Pharmacists Association (CPhA) urges the federal government ... all Canadians have the opportunity to protect themselves against ... The lack of access to HPV vaccination programs for ... needlessly putting the health of Canadians at risk. ... pose a significant threat to the health of Canadians," ...
Breaking Medicine Technology:EndoChoice to Report Second Quarter 2015 Financial Results on August 6, 2015 2OrthoSpace Enrolls First Patients in US IDE Study 2CPhA Calls for HPV Strategy for Young Men to Save Lives 2
... MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer ... processed from human amniotic membrane, announced today its results ... 30, 2011. The Company recorded record revenue ... over second quarter of 2011 revenue of $1,929,000 and ...
... Oct. 26, 2011 Reportlinker.com ... research report is available in ... Early Stage Drug Safety Strategies ... towards achieving clinical success ...
Cached Medicine Technology:MiMedx Group Announces Third Quarter 2011 Results 2MiMedx Group Announces Third Quarter 2011 Results 3MiMedx Group Announces Third Quarter 2011 Results 4MiMedx Group Announces Third Quarter 2011 Results 5MiMedx Group Announces Third Quarter 2011 Results 6MiMedx Group Announces Third Quarter 2011 Results 7MiMedx Group Announces Third Quarter 2011 Results 8MiMedx Group Announces Third Quarter 2011 Results 9MiMedx Group Announces Third Quarter 2011 Results 10Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... program modernization, today announced they have been selected by the Department of Vermont ... services for its Medicaid Management Information System (MMIS) and Integrated Contact Center System ...
(Date:7/6/2015)... ... 2015 , ... For over twenty years, Doctors on Liens has ... the company’s history the goal has been to be a comprehensive network of doctors ... And while Doctors on Liens has certainly achieved that goal, the addition of ...
(Date:7/6/2015)... ... July 06, 2015 , ... Human induced pluripotent stem cells ... generated from adult cells, such as blood or skin, can replicate indefinitely and ... , iPSC-derived cardiomyocytes have proven valuable in helping to detect ...
(Date:7/6/2015)... Woods, CA (PRWEB) , ... July 06, 2015 ... ... Water Revival System that eliminates 100% of all acids, chemicals and impurities; it ... suggested for drinking water because it contains harmful contaminants.  These harmful contaminants are ...
(Date:7/6/2015)... Pittsburgh, PA (PRWEB) , ... July 06, 2015 , ... ... experts in revising national guidelines for thyroid cancer testing to reflect newly available tests ... for when to use and how to interpret thyroid cancer tests is published in ...
Breaking Medicine News(10 mins):Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4Health News:Pristine Water Filters.com Offers The 1st Water Revival System That Re-Mineralizes Drinking Water and Eliminates All Impurities and Chemicals 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5
... , , WASHINGTON , Feb. 11 ... Women,s Dermatologic Society (WDS) announces the release of " ... stories, gems of advice, vignettes and insights drawn from 164 of ...  The book will be unveiled to the dermatology community at the ...
... 11 The Managed Care Executive Group has gathered some ... to meet March 21-24 in Fort Lauderdale Florida ... , The MCEG 2010 Annual Forum will be very unique and ... Mark McClellan , will kickoff the Forum with a comprehensive discussion ...
... aren,t in good enough shape to do it themselves, expert ... when digging out from the historic snowstorms of 2010: You ... the proper precautions. , "If you,re not a regular exerciser ... prepared for the stress of shoveling snow and you increase ...
... , NEW YORK , Feb. 11 ... Evidence has supported the link between poor oral health and such ... HIV/AIDS and osteoporosis may show preliminary signs in your mouth, before ... daily activities or habits can affect your oral health.  Therefore, it,s ...
... ... Webster cannot fully activate his arms or legs, but this year he will finish the Gasparilla ... by fellow veteran Marc Reed of St. Pete Beach, FL and by Ms. Florida US 2009, ... ...
... ... its global Integrated Clinical Environment™ (ICE™) solution. , ... (PRWEB) February 11, 2010 -- Sunquest , ... announces the latest release of its global Integrated Clinical Environment™ (ICE™) solution. ...
Cached Medicine News:Health News:Women's Dermatologic Society Marks 35th Anniversary with Release of Unprecedented Book of Wisdom and Inspiration 2Health News:Health Care Reform Thought Leaders to Meet in March 2Health News:Fitness a Factor in Snow Shoveling Injuries 2Health News:Health 'Bites': 8 Things You Didn't Know About Your Teeth 2Health News:Wheelchairs for Warriors Returns for 2010 Gasparilla Marathon 2Health News:Sunquest Announces Major Software Updates and Enhancements 2
Greenberg universal retractor case, with four compartments to hold various components....
Length-9 (229 mm) Tapered retractor blades....
Kit is supplied with four secondary bars. Secondary bars attach to primary bar. Length 12 (305 mm)....
Length 10 (254 mm). The Greenberg Handrest attaches to short coupler or a secondary bar....
Medicine Products: